메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Barrett’s esophagus (BE), characterized by a metaplastic change in the esophageal mucosa from a squamous to columnar mucosa with intestinal metaplasia, is the dominant pre-malignant lesion associated with esophageal adenocarcinoma (EAC), and BE confers a 30-125 folds higher risk of EAC. Although acid-suppressive medications can be used as a chemopreventive strategy for patients with BE, their effect on the incidence of EAC has been controversial.1 Recently, Singh et al2 reported a systematic review and meta-analysis of all studies that had investigated the association between acid-suppressive medications and EAC/high-grade dysplasia (HGD) in patients with BE. In a meta-analysis of 7 studies (2813 patients with BE, 317 cases of EAC/HGD), proton pump inhibitors (PPIs) were associated with a 71% risk reduction in progression to EAC/HGD among patients with BE (adjusted odds ratio, 0.29; 95% confidence interval, 0.12-0.79). This PPI effect was duration-dependent; PPI use extending beyond 2-3 years after BE diagnosis was associated with a lower risk of EAC/HGD, whereas PPI use for a shorter period was not associated with a protective effect. In addition, the PPI effect was independent of the presence of erosive esophagitis or reflux symptoms or the concomitant use of other putative chemopreventive agents such as aspirin and statins. However, histamine receptor antagonists had no significant effect on EAC risk modification in patients with BE. Therefore, the authors suggested that PPI use should be considered as a chemopreventive method in patients with BE.

목차

등록된 정보가 없습니다.

참고문헌 (11)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0